BIO Statement on National Academies’ Consensus Study on Human Gene EditingFeb 14 2017
Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement regarding the Consensus Study on Human Gene Editing, released today by the Human Gene Editing Initiative of the National Academies of Sciences and Medicine (NAS/NAM)
|
|
EU’s Anti-Science Comitology Reform Threatens InnovationFeb 14 2017
Washington, D.C. (February 14, 2017) – The European Commission announced today a proposal to revise its Comitology Regulation forcing policy decisions to individual EU member countries.
|
|
BIO Announces Gary Andres as the New Senior Executive Vice President of Public AffairsFeb 14 2017
Long-time Majority Staff Director of the House Energy and Commerce Committee Dr. Gary Andres joins BIO as Senior Executive Vice President of Public Affairs. |
|
Registration Now Open for the 14th Annual BIO World Congress on Industrial BiotechnologyFeb 8 2017
BIO announced registration and housing are now open for the 2017 World Congress on Industrial Biotechnology. The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Canada.
|
|
BIO Statement on President Trump’s Comments Supporting Biopharmaceutical Competition and InnovationJan 31 2017
Washington, DC (January 31, 2017) – BIO issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation:
|
|
BIO Statement on USDA and FDA Actions related to Pre-market Regulatory Oversight of Plant and Animal OrganismsJan 18 2017
The U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) published today four documents related to the pre-market regulatory oversight of a variety of biology-based agricultural tools, including genetically engineered plants and plants and animals derived from certain newer precision breeding techniques, such as genome editing.
|
|
BIO’s Jim Greenwood Meets with India’s PM ModiJan 13 2017
Delivers Message: India Must Protects Innovators’ Work Product
|
|
BIO Statement on Proposed Maryland Drug Pricing LegislationJan 10 2017
BIO's statement regarding proposed drug pricing legislation within the Maryland Senate.
|
|
BIO CEO & Investor Conference Programming AnnouncedDec 15 2016
BIO announced programming for the 19th annual BIO CEO & Investor Conference. Held February 13-14 at the Waldorf Astoria in New York, the annual conference provides an environment for investors, analysts, industry executives and others to discover trends in life sciences, network with peers and potential partners and explore investment opportunities. Established and emerging publicly traded and select private biotech companies are the focus of the event.
|
|
BIO Applauds Senate Passage of the 21st Century Cures ActDec 7 2016
Washington, DC (December 7, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. Senate:
|
